Ra Capital Management as of June 30, 2021
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 92 positions in its portfolio as reported in the June 2021 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Ascendis Pharma A/s Sponsored Adr (ASND) | 14.4 | $895M | 6.8M | 131.55 | |
Novavax Com New (NVAX) | 8.7 | $544M | 2.6M | 212.31 | |
Forma Therapeutics Hldgs SHS | 3.6 | $224M | 9.0M | 24.89 | |
Janux Therapeutics (JANX) | 3.5 | $216M | 8.7M | 24.95 | |
Vor Biopharma (VOR) | 3.3 | $207M | 11M | 18.65 | |
Aerovate Therapeutics (AVTE) | 3.0 | $189M | 8.3M | 22.83 | |
Nkarta (NKTX) | 2.9 | $178M | 5.6M | 31.69 | |
Macrogenics (MGNX) | 2.6 | $160M | 5.9M | 26.86 | |
Connect Biopharma Hldgs Ads (CNTB) | 2.2 | $137M | 7.0M | 19.53 | |
Tg Therapeutics (TGTX) | 2.1 | $130M | 3.3M | 38.79 | |
ImmunoGen | 1.9 | $121M | 18M | 6.59 | |
Atea Pharmaceuticals (AVIR) | 1.9 | $115M | 5.4M | 21.48 | |
Iteos Therapeutics (ITOS) | 1.8 | $113M | 4.4M | 25.65 | |
Day One Biopharmaceuticals I (DAWN) | 1.8 | $113M | 5.0M | 22.77 | |
Axsome Therapeutics (AXSM) | 1.8 | $112M | 1.7M | 67.46 | |
Phathom Pharmaceuticals (PHAT) | 1.7 | $105M | 3.1M | 33.85 | |
Instil Bio | 1.5 | $94M | 4.9M | 19.32 | |
Rocket Pharmaceuticals (RCKT) | 1.5 | $93M | 2.1M | 44.29 | |
89bio (ETNB) | 1.5 | $93M | 5.0M | 18.70 | |
Zogenix Com New | 1.5 | $91M | 5.3M | 17.28 | |
Vaxcyte (PCVX) | 1.4 | $87M | 3.9M | 22.51 | |
Kinnate Biopharma | 1.3 | $84M | 3.6M | 23.28 | |
Graphite Bio | 1.3 | $83M | 2.7M | 30.73 | |
Travere Therapeutics (TVTX) | 1.3 | $82M | 5.6M | 14.59 | |
Werewolf Therapeutics (HOWL) | 1.2 | $75M | 4.3M | 17.44 | |
Rhythm Pharmaceuticals (RYTM) | 1.1 | $71M | 4.9M | 14.59 | |
Cyteir Therapeutics | 1.1 | $70M | 3.2M | 21.40 | |
Gh Research Ordinary Shares (GHRS) | 1.0 | $65M | 3.0M | 21.73 | |
Olema Pharmaceuticals (OLMA) | 1.0 | $60M | 2.2M | 27.98 | |
Dyne Therapeutics (DYN) | 0.9 | $59M | 2.8M | 21.04 | |
Pmv Pharmaceuticals (PMVP) | 0.9 | $58M | 1.7M | 34.16 | |
Kala Pharmaceuticals | 0.9 | $58M | 11M | 5.30 | |
Curis Com New | 0.9 | $58M | 7.1M | 8.07 | |
Cerevel Therapeutics Hldng I (CERE) | 0.9 | $56M | 2.2M | 25.62 | |
Edgewise Therapeutics (EWTX) | 0.9 | $56M | 2.6M | 21.33 | |
Orchard Therapeutics Ads | 0.9 | $54M | 12M | 4.39 | |
Silverback Therapeutics (SPRY) | 0.9 | $54M | 1.7M | 30.89 | |
Verve Therapeutics (VERV) | 0.9 | $53M | 880k | 60.25 | |
C4 Therapeutics Com Stk (CCCC) | 0.8 | $52M | 1.4M | 37.84 | |
Wave Life Sciences SHS (WVE) | 0.8 | $52M | 7.8M | 6.66 | |
Trillium Therapeutics Com New | 0.8 | $51M | 5.3M | 9.70 | |
Achilles Therapeutics Sponsored Ads (ACHL) | 0.8 | $49M | 5.0M | 9.79 | |
Chemocentryx | 0.8 | $47M | 3.5M | 13.39 | |
Kalvista Pharmaceuticals (KALV) | 0.7 | $46M | 1.9M | 23.96 | |
Ardelyx (ARDX) | 0.7 | $46M | 6.1M | 7.58 | |
Solid Biosciences | 0.7 | $45M | 12M | 3.66 | |
Design Therapeutics (DSGN) | 0.7 | $44M | 2.2M | 19.89 | |
Geron Corporation (GERN) | 0.7 | $43M | 30M | 1.41 | |
Satsuma Pharmaceuticals Ord | 0.7 | $42M | 5.9M | 7.05 | |
Legend Biotech Corp Sponsored Ads (LEGN) | 0.6 | $40M | 978k | 41.05 | |
Bolt Biotherapeutics (BOLT) | 0.6 | $37M | 2.4M | 15.46 | |
Inozyme Pharma (INZY) | 0.5 | $34M | 2.0M | 17.04 | |
Verona Pharma Sponsored Ads (VRNA) | 0.5 | $33M | 5.1M | 6.54 | |
Black Diamond Therapeutics (BDTX) | 0.5 | $32M | 2.6M | 12.19 | |
Akouos | 0.5 | $29M | 2.3M | 12.55 | |
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.5 | $28M | 1.3M | 22.21 | |
Century Therapeutics (IPSC) | 0.4 | $27M | 914k | 29.34 | |
Nautilus Biotechnology (NAUT) | 0.4 | $25M | 2.5M | 10.10 | |
Cytomx Therapeutics (CTMX) | 0.4 | $22M | 3.5M | 6.33 | |
Scpharmaceuticals (SCPH) | 0.3 | $17M | 2.7M | 6.11 | |
Larimar Therapeutics (LRMR) | 0.2 | $15M | 1.5M | 9.82 | |
Bctg Acquisition Corp | 0.2 | $14M | 1.3M | 11.38 | |
Entera Bio SHS (ENTX) | 0.2 | $14M | 2.4M | 5.98 | |
Bcls Acquisition Corp Com Cl A | 0.2 | $13M | 1.3M | 10.53 | |
Concert Pharmaceuticals I equity | 0.2 | $13M | 3.0M | 4.22 | |
Catabasis Pharmaceuticals In Com New | 0.2 | $13M | 5.9M | 2.11 | |
Milestone Pharmaceuticals (MIST) | 0.2 | $12M | 2.2M | 5.50 | |
Therapeutics Acquisition Cor Com Cl A | 0.2 | $11M | 1.1M | 10.27 | |
Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $11M | 1.3M | 8.99 | |
Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.2 | $11M | 1.0M | 10.72 | |
Ocular Therapeutix (OCUL) | 0.2 | $11M | 750k | 14.18 | |
Phasebio Pharmaceuticals | 0.2 | $11M | 2.9M | 3.72 | |
Ikena Oncology (IKNA) | 0.2 | $11M | 750k | 14.04 | |
Oric Pharmaceuticals (ORIC) | 0.2 | $10M | 584k | 17.69 | |
Frazier Lifesciences Acquisition Unit 12/09/2025 | 0.2 | $10M | 1.0M | 10.05 | |
Fs Development Corp Ii Com Cl A | 0.2 | $10M | 1.0M | 9.98 | |
Therapeuticsmd | 0.1 | $9.3M | 7.8M | 1.19 | |
Cullinan Oncology (CGEM) | 0.1 | $9.0M | 350k | 25.75 | |
Cogent Biosciences (COGT) | 0.1 | $8.3M | 1.0M | 8.11 | |
Biomea Fusion (BMEA) | 0.1 | $7.8M | 500k | 15.61 | |
CVRX (CVRX) | 0.1 | $7.7M | 275k | 28.00 | |
5 01 Acquisition Corp Com Cl A | 0.1 | $7.5M | 750k | 9.97 | |
Helix Acquisition Corp Com Cl A | 0.1 | $7.2M | 700k | 10.35 | |
Health Sciences Acq Corp 2 Ord Shs | 0.1 | $6.4M | 625k | 10.20 | |
Miragen Therapeutics (VRDN) | 0.1 | $5.7M | 312k | 18.29 | |
Syros Pharmaceuticals | 0.1 | $4.9M | 900k | 5.45 | |
Aerpio Pharmaceuticals | 0.1 | $4.6M | 2.7M | 1.69 | |
Cerevel Therapeutics Hldng *w Exp 06/09/2027 (CEREW) | 0.1 | $3.4M | 233k | 14.39 | |
Intellia Therapeutics (NTLA) | 0.0 | $2.4M | 15k | 161.93 | |
Imara | 0.0 | $2.0M | 249k | 7.90 | |
Seres Therapeutics (MCRB) | 0.0 | $1.9M | 5.1M | 0.37 | |
Reneo Pharmaceuticals (RPHM) | 0.0 | $580k | 62k | 9.32 |